Faculty Information
   Activities & Events
   Melanoma Care Centers
   Slide Library
   Polling Results
   Patient Resources
   Contact Us
Log In


What's different about the 7th edition of the AJCC staging system?

CME Course Duration:

Start Date: January 2009
End Date: January 2010

Merrick I. Ross, MD, FACS
Professor of Surgical Oncology
University of Texas M.D. Anderson Cancer Center
Houston, TX

Featured Topic Information:
Please click here to view a webcast (registration required)
Please click here to view the slide library (registration required)
Please click here to listen to the audio (registration required)
Please click here to take the post test and evaluation (registration required)
Please click here if you have any comments or questions relating to this topic

Target Audience

This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who treat or screen for melanoma.

Educational Objective

Interpret changes to the latest edition of the AJCC staging system for melanoma, and extrapolate those changes to clinical practice

Faculty Disclosure Statement

Dr. Merrick I. Ross has disclosed he has participated on the speaker’s bureau for Schering-Plough Corporation, and Genentech, Inc.

This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Paradigm Medical Communications, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.

Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.